Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Suzuken Co., Ltd. (9987.T)
Nagoya, JP
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions. Its Pharmaceutical Distribution Business focuses on sourcing a wide array of products, including ethical drugs, diagnostic reagents, medical devices, and other health-related items directly from manufacturers, and then supplying these to healthcare institutions and pharmacies. The Pharmaceutical Manufacturing Business is dedicated to the research, development, production, and commercialization of prescription pharmaceuticals and diagnostic tools, with a particular emphasis on diabetes and kidney-related conditions. Through its Pharmacy Business segment, Suzuken offers services via family pharmacists, works to enhance the efficiency of local pharmacy operations, and provides educational support. The Healthcare-Related Services Business encompasses a variety of support functions, such as contract distribution for manufacturers, the distribution of orphan drugs, and nursing care services. This segment is also involved in the development, manufacturing, and sale of medical equipment, including electrocardiographs, blood pressure monitors, stethoscopes, general medical supplies, and health promotion devices. Furthermore, Suzuken Co., Ltd. publishes medical journals for healthcare professionals and collaborates with Bushu Pharmaceuticals Ltd. to provide specialized contract drug services. The company was established in 1932 and is headquartered in Nagoya, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.21% | -0.89% | -10.34% | -14.53% | -10.75% | -14.38% | +3.40% | +36.46% | +49.08% | +50.13% | +95.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+3.6% Q1'26: +7.1% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+20.0% ★ Q1'26: +99.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+0.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.5% Q1'26: +1.5% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+9.3% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-7.9% ★ Q1'26: -6.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.97T
est: 1.98T (-0.6%)
|
2.23T
est: 2.22T (+0.3%)
|
2.13T
est: 2.13T (-0.2%)
|
2.12T
est: 2.11T (+0.7%)
|
2.13T
est: 2.10T (+1.5%)
|
2.21T
est: 2.21T (+0.3%)
|
2.13T
est: 2.14T (-0.4%)
|
2.24T
est: 2.21T (+1.2%)
|
2.31T
est: 2.31T (+0.3%)
|
2.39T
est: 2.40T (-0.4%)
|
2.40T
est: 2.43T (-1.3%)
|
2.48T
2.47T – 2.48T
+1.9% YoY
|
2.55T
2.54T – 2.56T
+2.9% YoY
|
2.63T
2.55T – 2.69T
+3.2% YoY
|
2.70T
2.70T – 2.70T
+2.5% YoY
|
2.78T
2.73T – 2.81T
+3.1% YoY
|
| EBITDA |
25.39B
est: 35.64B (-28.8%)
|
41.18B
est: 39.96B (+3.1%)
|
31.41B
est: 38.34B (-18.1%)
|
31.80B
est: 37.93B (-16.2%)
|
38.79B
est: 37.79B (+2.6%)
|
44.00B
est: 39.70B (+10.8%)
|
19.47B
est: 38.44B (-49.4%)
|
30.14B
est: 39.79B (-24.3%)
|
41.45B
est: 41.49B (-0.1%)
|
43.62B
est: 64.60B (-32.5%)
|
49.19B
est: 65.59B (-25.0%)
|
66.81B
66.61B – 66.97B
+1.9% YoY
|
68.78B
68.53B – 69.03B
+2.9% YoY
|
70.96B
68.67B – 72.45B
+3.2% YoY
|
72.73B
72.73B – 72.73B
+2.5% YoY
|
74.96B
73.60B – 75.89B
+3.1% YoY
|
| EBIT |
13.24B
est: 26.99B (-50.9%)
|
28.24B
est: 30.26B (-6.6%)
|
18.71B
est: 29.03B (-35.5%)
|
19.74B
est: 28.72B (-31.3%)
|
27.23B
est: 28.62B (-4.9%)
|
32.57B
est: 30.06B (+8.4%)
|
9.16B
est: 29.11B (-68.5%)
|
20.12B
est: 30.13B (-33.2%)
|
32.61B
est: 31.42B (+3.8%)
|
34.88B
est: 50.13B (-30.4%)
|
37.13B
est: 50.90B (-27.1%)
|
51.84B
51.68B – 51.97B
+1.9% YoY
|
53.37B
53.17B – 53.56B
+2.9% YoY
|
55.06B
53.29B – 56.22B
+3.2% YoY
|
56.43B
56.43B – 56.43B
+2.5% YoY
|
58.16B
57.11B – 58.89B
+3.1% YoY
|
| Net Income |
18.92B
est: 13.47B (+40.5%)
|
28.96B
est: 19.73B (+46.8%)
|
21.31B
est: 16.96B (+25.6%)
|
18.82B
est: 13.68B (+37.6%)
|
30.21B
est: 23.14B (+30.5%)
|
28.21B
est: 21.64B (+30.4%)
|
7.90B
est: 7.50B (+5.3%)
|
14.39B
est: 12.88B (+11.8%)
|
20.35B
est: 17.76B (+14.6%)
|
29.02B
est: 26.74B (+8.5%)
|
34.50B
est: 31.97B (+7.9%)
|
34.90B
33.52B – 36.27B
+9.2% YoY
|
27.83B
27.65B – 28.02B
-20.2% YoY
|
27.41B
24.50B – 33.96B
-1.5% YoY
|
33.16B
32.22B – 34.10B
+21.0% YoY
|
34.62B
33.80B – 35.18B
+4.4% YoY
|
| SGA |
160.69B
est: 128.08B (+25.5%)
|
168.51B
est: 143.60B (+17.4%)
|
166.87B
est: 137.76B (+21.1%)
|
161.10B
est: 136.29B (+18.2%)
|
156.19B
est: 135.82B (+15.0%)
|
156.90B
est: 142.65B (+10.0%)
|
145.23B
est: 138.14B (+5.1%)
|
142.62B
est: 142.98B (-0.3%)
|
144.14B
est: 149.11B (-3.3%)
|
147.09B
est: 150.20B (-2.1%)
|
151.58B
est: 152.50B (-0.6%)
|
155.35B
154.86B – 155.71B
+1.9% YoY
|
159.91B
159.33B – 160.49B
+2.9% YoY
|
164.98B
159.67B – 168.45B
+3.2% YoY
|
169.10B
169.10B – 169.10B
+2.5% YoY
|
174.28B
171.13B – 176.45B
+3.1% YoY
|
| EPS |
190.81
est: 177.45 (+7.5%)
|
292.12
est: 259.97 (+12.4%)
|
216.92
est: 223.53 (-3.0%)
|
198.21
est: 180.26 (+10.0%)
|
322.72
est: 304.95 (+5.8%)
|
310.26
est: 285.10 (+8.8%)
|
88.51
est: 98.77 (-10.4%)
|
163.18
est: 169.73 (-3.9%)
|
236.46
est: 233.72 (+1.2%)
|
357.87
est: 383.88 (-6.8%)
|
454.58
est: 458.94 (-1.0%)
|
499.26
479.57 – 518.92
+8.8% YoY
|
398.18
395.59 – 400.76
-20.2% YoY
|
441.17
350.51 – 485.87
+10.8% YoY
|
474.41
460.96 – 487.86
+7.5% YoY
|
495.20
483.58 – 503.21
+4.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chie Takahashi | Sr. Exec. Officer, Head of Medical & Nursing Support Bus. Div and Director | — | female |
| Hirofumi Tanaka | Executive MD, Senior GM of Healthcare Distribution Business Headquarters & Director | — | male |
| Shigeru Asano | President, Chief Executive Officer & Director | — | male |
| Toyoaki Ota | Senior Executive Officer & General Manager of Human Resources and General Affairs Division | — | — |
| Yoshihiro Otsuka | Senior Executive Officer & Head of the Pharmacy Division | — | — |
| Yuichi Yamamoto | Executive Officer, Group Planning Division Chief & Corporate Planning Department Chief | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9987.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
